YolTech Pharmaceuticals
a Shanghai in-vivo gene-editing company founded in 2021, building AAV-delivered base-editor platforms for cardiovascular and metabolic targets, backed by a more than 300 million yuan B round led by the AstraZeneca-CICC healthcare fund.
- Country
- China
Pilot
AAV-delivered in-vivo base editing, >300M yuan B round (AZ-CICC fund)
cn
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| In-vivo gene therapy: AAV and lentiviral vectors | therapeutics-platforms | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.